Publication:
Efficacy of fluoroscopy-guided triple shoulder injection for older patients with nonspecific shoulder pain

dc.contributor.authorsCuce, Isa; Sencan, Savas; Demir, Fatmagul Ulku; Koc, Ali; Calis, Mustafa
dc.date.accessioned2022-03-12T22:38:45Z
dc.date.accessioned2026-01-11T19:03:27Z
dc.date.available2022-03-12T22:38:45Z
dc.date.issued2019
dc.description.abstractKey Summary PointsAimThe study was to evaluate the effects of fluoroscopy-guided triple shoulder injection (i.e. injection into glenohumeral joint, subacromial space, and acromioclavicular joint) on pain and function in older patients with nonspecific shoulder pain.FindingsA significant improvement was detected in pain, and function at 3 and 12 weeks after injection compared with baseline.MessageFluoroscopy-guided triple shoulder injection offers a therapeutic option for older patients with nonspecific shoulder pain. AbstractPurposeNonspecific shoulder pain is a common complaint in older adults that impairs physical function by restricting the range of joint movement, and causing severe pain. The study evaluated the effects of fluoroscopy-guided triple shoulder injection [i.e., injection into glenohumeral (GH) joint, subacromial (SA) space, and acromioclavicular (AC) joint] on pain, function, and range of motion in older patients with nonspecific shoulder pain.MethodsA total of 43 patients who were aged 65years and older and diagnosed with nonspecific shoulder pain were included in this prospective, non-randomized clinical trial; 65.1% of the patients were female and mean age was 70.25.0. Under fluoroscopic guidance, a mixture of methylprednisolone and bupivacaine was injected into the GH joint, SA space and AC joint. Patients were evaluated as per the Numeric Rating Scale for Pain (NRS-Pain), the Shoulder Pain and Disability Index (SPADI), and the active range of motion (AROM) at baseline, and again at 3 and 12weeks after the injection.ResultsA statistically significant improvement was detected in NRS-Pain, SPADI, and AROM at 3 and 12weeks after injection compared with baseline. The change in SPADI score from baseline was higher than the minimal detectable change in 67.4% of patients at 12weeks. The SPADI score at baseline was positively correlated with the post-injection SPADI score at 3 and 12weeks.Conclusions In older patients with nonspecific shoulder pain, fluoroscopy-guided triple shoulder injection provides significant improvements in pain and physical function with low complication rates during the 12-week follow-up.
dc.identifier.doi10.1007/s41999-018-00159-9
dc.identifier.eissn1878-7657
dc.identifier.issn1878-7649
dc.identifier.pubmed34652724
dc.identifier.urihttps://hdl.handle.net/11424/235723
dc.identifier.wosWOS:000476771900008
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofEUROPEAN GERIATRIC MEDICINE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAged
dc.subjectShoulder pain
dc.subjectInjections
dc.subjectFluoroscopy
dc.subjectMagnetic resonance imaging
dc.subjectSUPRASCAPULAR NERVE BLOCK
dc.subjectCORTICOSTEROID INJECTIONS
dc.subjectABNORMALITIES
dc.subjectPOPULATION
dc.subjectPREVALENCE
dc.subjectULTRASOUND
dc.subjectMANAGEMENT
dc.titleEfficacy of fluoroscopy-guided triple shoulder injection for older patients with nonspecific shoulder pain
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage602
oaire.citation.issue4
oaire.citation.startPage595
oaire.citation.titleEUROPEAN GERIATRIC MEDICINE
oaire.citation.volume10

Files